Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
09 2023
Historique:
received: 09 11 2022
revised: 24 06 2023
accepted: 05 07 2023
medline: 4 9 2023
pubmed: 16 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

Chronic thromboembolic pulmonary hypertension (CTEPH) remains an underdiagnosed disease. Anticoagulation is essential in its therapy to prevent recurrent venous thromboembolism (VTE). According to some international guidelines, vitamin K antagonists (VKA) remain the gold standard. Nevertheless, direct oral anticoagulants (DOAC) are widely used, partly because of numerous advantages. The objective of this study was to determine if DOAC is an effective and safe alternative to VKA in CTEPH patients. A retrospective observational study was conducted between 2001 and 2021 in a CTEPH Clinic of a tertiary care hospital. We recorded demographic characteristics, anticoagulant therapies and pulmonary hypertension treatments received. Safety outcomes were bleeding events and deaths while efficacy outcomes were recurrent VTE events. Among the study population (N = 205), the distribution of anticoagulant used transitioned from majority on VKA to majority on DOAC. In 2020, 23 (19 %) were on VKA and 97 (78 %) on DOAC. Among 11 VTE events occurring during follow-up, 7 were in the VKA group (1.10 %/person-year) and 1 in the DOAC group (0.32 %/person-year). Rates of VTE recurrence were not significantly different in those treated with DOAC compared to VKA (P = 0.21). Total bleeding rate on VKA (2.52 %/person-year) and DOAC (2.52 %/person-year) were the same (P = 1.00). Among 27 patients who died, no deaths occurred as a consequence of bleeding or VTE events. Bleeding and VTE events were not higher in CTEPH patients receiving DOAC compared to VKA which adds confidence to considering DOAC as an effective and safe alternative for long term anticoagulation in CTEPH patients.

Identifiants

pubmed: 37453256
pii: S0049-3848(23)00214-1
doi: 10.1016/j.thromres.2023.07.002
pii:
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0
Vitamin K 12001-79-5

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-145

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ilham Benzidia (I)

Division of Internal Medicine and Division of Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Montreal, QC, Canada; Center of Excellence in Thrombosis and Anticoagulation Care (CETAC), Jewish General Hospital, McGill University, Montreal, QC, Canada.

Chantal Robitaille (C)

Division of Pulmonary Diseases, Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Ali Abualsaud (A)

Center for Pulmonary Vascular Disease, Division of Cardiology, Azrieli Heart Center, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Laura McDonald (L)

Division of Internal Medicine and Division of Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Montreal, QC, Canada.

Lyda Lesenko (L)

Center for Pulmonary Vascular Disease, Division of Cardiology, Azrieli Heart Center, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Jean-François Morin (JF)

Division of Cardiac Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.

David Langleben (D)

Center for Pulmonary Vascular Disease, Division of Cardiology, Azrieli Heart Center, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Susan R Kahn (SR)

Division of Internal Medicine and Division of Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Montreal, QC, Canada; Center of Excellence in Thrombosis and Anticoagulation Care (CETAC), Jewish General Hospital, McGill University, Montreal, QC, Canada.

Andrew Hirsch (A)

Division of Pulmonary Diseases, Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada; Center of Excellence in Thrombosis and Anticoagulation Care (CETAC), Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: andrew.hirsch@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH